North South Divide Exists In UK Digestive Health
More northern women feel bloating and gurgling than their southern counterparts with up to 70% of them likely to experience it at any one time, according to a TNS survey commissioned by Danone(1). Women from the West Midlands and Yorkshire and Humberside fared the worst (71%), with Greater London and the South West experiencing the least amount of bloated feelings.
As Population Ages And Need For Palliative Care Grows, Experts Tackle New Challenge For The First Time At European Meeting
Experts from across Europe are gathering at a scientific symposium held at the fifth European Association for Palliative Care (EAPC) congress in Trondheim, Norway, on the 29th May, to discuss the challenges of managing an overlooked and distressing symptom that affects large numbers of patients receiving opioids as part of palliative care management for advanced illness: opioid-induced constipation (OIC).
Movetis Files RESOLOR R With EMEA For The Indication Of Chronic Constipation
Movetis announced that the European Medicines Agency (EMeA) has accepted the Marketing Authorization Application (MAA) submission for RESOLOR (prucalopride) as a treatment for chronic constipation in adults in whom laxatives fail to provide adequate relief.
Study Offers Relief For Sufferers Of Severe Chronic Constipation
A new medication appears to offer significant relief to patients with severe chronic constipation while minimizing the likelihood of cardiac-related side effects, according to results of a study published this week in the New England Journal of Medicine.
AMITIZA R lubiprostone 8 Mcg Now Available To Treat Irritable Bowel Syndrome With Constipation In Adult Women
Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. announced that AMITIZA(R) (lubiprostone) 8 mcg capsules are now available by prescription in pharmacies across the U.S. for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older.
Novel Toxin Receptor Discovered For Helicobacter Pylori
Helicobacter pylori is one tough bug. It can survive in the human stomach, a zone with a pH somewhere between that of lemon juice and battery acid. Now researchers have discovered how an H. pylori toxin gets into cells, a feat that helps the bacterium live in one of the most inhospitable environments in the body.
News From The Journals Of The American Society For Microbiology
Immune Cells May Induce Gastritis During H. pylori InfectionFor the first time researchers from Australia and The Netherlands examine the inflammatory response induced by macrophages that may contribute to the development of gastritis during Helicobacter pylori infection in mice.
Chronic Constipation - Three Presentations And Four Additional Posters Reinforce Efficacy And Safety Profile Of RESOLOR
Movetis NV, a European-based GI specialist pharmaceutical company, announces that it has presented substantial new data from different studies this week at the prestigious Digestive Disease Week (DDW) 2008 Congress.
Early Esophageal Cancer And Pre Cancer Eliminated With Non Surgical Treatment Combination
BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, announced the publication of two related European trials which report a 100% eradication rate for early esophageal cancer and pre-cancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system.
Ironwood Pharmaceuticals And Forest Laboratories Announce Presentation Of Linaclotide Phase 2b Chronic Constipation Study Results
Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled study assessing the safety and efficacy of linaclotide in patients with chronic constipation (CC).